Day One

• Developing an iterative and AI-optimized circular RNA platform that results in robust protein expression and a manufacturing process that provides high purity and high yield at a low cost
• Showcasing microneedle technology resulting in high protein production and therapeutic response
• Outlining how circular RNA therapeutics have shown outstanding efficacy and are considerably better than a comparable linear mRNA

• Exploring a brief overview of circular RNA technologies
• Discussing end-to-end self-targeting and splicing (STS)-mediated self-circularization for the preparation of scarless circRNA
• Learning functional validation: Application of circular RNA in CAR-T therapy

• Reviewing strategies for optimizing circRNA generation
• Discussing the design and optimization of a cicRNA purification strategy
• Evaluating purified circRNA for therapeutic applications in human rare disease

This is your opportunity to have face-to-face conversations with fellow attendees. Progress your RNA candidates forward and make connections with global pharma and biotech working on RNA, vaccine development, cell and gene therapy, as well as global service providers, in a mix of pre-organized and ad-hoc networking.

• Engineering AI-driven mRNA cancer vaccines using the Th-Vac® platform to enable precision antigen selection and potent MHC class II–restricted CD4⁺T-cell activation in solid tumors
• Integrating a multi-epitope design strategy that coordinates CD4⁺ T helper and CD8⁺ cytotoxic T-cell responses, establishing a “helper-killer axis” for amplified and sustained anti-tumor immunity
• Advancing a differentiated immunotherapy paradigm that overcomes the resistance limitations of conventionally targeted therapies by inducing durable, adaptive immune responses against clinically relevant tumor antigens

• Session details to be announced

• Benchmarking of mRNA cancer vaccine design
• Exploring new ways to manufacture mRNA cancer vaccines
• Discussing precision delivery of mRNA-cancer vaccines with bispecific PEG engagers

• Overcoming the challenges of small-scale GMP manufacturing capability on CMO/CDMO services for the personalized cancer vaccine, contributing to the increase in cost of manufacturing
• Harmonizing the regulatory guidelines around the personalized cancer vaccine
• Discussing the potential marketability of the personalized cancer vaccines in the future

Lunch for all attendees will be served in a designated area.

This is your opportunity to have face-to-face conversations with fellow attendees. Progress your RNA candidates forward and make connections with global pharma and biotech working on RNA, vaccine development, cell and gene therapy, as well as global service providers.

• Presenting an overview of Abogen’s mRNA and LNP platform
• Showcasing clinical progress of TCE/in vivo CART
• Sharing future perspectives of mRNA therapeutics

• Discussing tissue specific delivery with hydrophilic nanoparticle
• Reviewing antigen-specific immune tolerance
• Exploring tunable immune modulation

As innovation continues to unlock scalable, cost-effective and commercially viable RNA therapeutics and vaccines, there has never been a more exciting time to connect, collaborate and exchange ideas.

Join our dynamic poster session to showcase your latest data, spark new conversations and gain exclusive early insights into the cutting-edge work shaping the RNA, cell, and gene therapy fields.

• Leveraging spleen tropism of LNPs using a novel targeting ionizable lipid
• Engineering active targeting LNP platforms for cell-specific delivery
• Evaluating immune cell-targeting LNPs in immunotherapy, autoimmune disease, and in vivo CAR/TCR applications

• Applying Structure-Activity Relationship (SAR) modeling and AI-guided molecular design to develop a proprietary lipid library with an optimized therapeutic index and enhanced clinical tolerability
• Identifying and selecting LNP formulations tailored for high-efficiency hepatic delivery, facilitating the technical transition from transient protein replacement to permanent genetic intervention with minimal off-target toxicity
• Developing LNP formulations specifically optimized to maximize T-cell delivery efficiency, enabling precise in vivo CAR-T cell programming through systemic mRNA delivery

• Developing a branched ionizable lipid nanoparticle (FL0445-LNP) that enables potent delivery of both linear mRNA and Cap-cirRNA
• Exploring how FL0445‑LNP exhibits an improved safety profile with reduced immunogenicity compared with clinical benchmark LNPs
• Sharing how Cap‑cirRNA delivered via FL0445‑LNP achieves superior glycemic control over linear mRNA in obese mice

• Overview of DegradaBALL as next-generation drug delivery system (DDS) platform technology
• Explore how excellent human safety has been confirmed in Phase I clinical trials of siRNA and mRNA pipelines employing DegradaBALL
• Discuss DegradaBALL applications in cancer immunotherapy